CytomX Therapeutics, Inc. — Director's Dealing 2017

Oct 4, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2017-10-02

Reporting Person: McCarthy Sean A. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-10-02	Common Stock	M	9562	$0.945	Acquired	13807	Direct
2017-10-02	Common Stock	S	9562	$18.57	Disposed	4245	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-02	Stock Option (right to buy)	$0.945	M	9562	Disposed	2023-02-25	Common Stock (9562)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	158737	Indirect

Footnotes

F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.10 to $18.97, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees.

F4: 100% of the shares subject to the option are fully vested and exercisable.